leucine zipper protein 2Genealiases: KFSP2566 · PRO6246
Q-omics provides the consensus-scored LUZP2 profile across patient tissues and cancer cell-line models. LUZP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, LUZP2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LUZP2 RNA expression shows 12,253 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, COAD, and TGCT as cancer lineages where LUZP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LUZP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LUZP2 survival associations across molecular data types. LUZP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LUZP2 RNA expression–survival associations across cancer types. High LUZP2 expression shows unfavorable associations in UVM, ACC and KIRP, but favorable associations in LUSC, LGG and LIHC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for LUZP2 RNA expression.
This table summarizes LUZP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LUZP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LUZP2 shows lower tumor expression in COAD, KICH, BRCA, READ and LUAD and higher tumor expression in LIHC. The COAD box plot shows higher LUZP2 RNA expression in normal versus tumor tissue (log2 FC = −0.842, t-test p < 0.001).
This table shows molecular features associated with LUZP2 in patient tissues and cancer cell lines. In patient samples, LUZP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LUZP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and URINARY_TRACT.
